Lersivirine
473921-12-9
0.98%
2026-07-05
Coenzymes,Inhibito,Enzymes,Zymogens,Substrates,Native Microorganism Creatine Amidinohydrolase
-
Product Description
-
Seller Information
-
Description
ProductName Lersivirine Cat No CEI-1396 Description Lersivirine (UK-453061) is a next-generation non-nucleoside inhibitor of reverse transcriptase under development for the treatment of HIV-1 infection. Product Overview Lersivirine (UK-453061) is a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI)for human immunodeficincy virus (HIV) infection with IC50 value of 119 nM. HIV is a retro virus that causes HIV infection and acquired immunodeficiency syndrome (AIDS). It may infect vital cells of human immune system such as helper T cells and dendritic cells. HIV transcriptase plays an important role in the infection process. HIV carries a reverse transcriptase which can transcript single-stranded virus RNA into double-stranded DNA. When the virus anchor to the target cell surface, the reverse transcriptase will be injected into host cell, there it may complete the transcription. And the transcribed DNA is able to integrate into host genome to complete infection and viral replication. Lersivirine (UK-453061) is a NNRTI with a unique resistance profile that exhibits potent antiretroviral activity against wild-type HIV and clinically relevant NNRTI-resistant strains. When lersivirine was tested with a panel of isolated wild-type and drug-resistant HIV reverse transcriptase, it exhibited excellent inhibitory activity, which confirmed the high potency of it as the next-generation anti-HIV NNRTI. The compound also has good aqueous solubility and formulation characteristics which enable further in vivo evaluation. Mated Crl:CD1 mice were administered 0, 150, 350, and 500 mg/kg lersivirine once daily by oral gavage on gestation days 6 to 17, followed by cesarean section on gestation day 18. The first 2 days of dosing for the high-dose group were done at 250 mg/kg to allow induction of hepatic metabolizing enzymes, after which the dose was increased to 500 mg/kg/day. Exposure of lersivirine did not cause any increases in external, visceral, or skeletal malformation, which demonstrated lersivirine is not teratogenic in mice. CAS No 473921-12-9 Molecular Weight 310.35 Purity 0.98 Storage Store at -20°C Synonyms UK-453061; UK453061; UK 453061 Targets NNRT Molecular Formula C17H18N4O2 Chemical Name 5-[3,5-diethyl-1-(2-hydroxyethyl)pyrazol-4-yl]oxybenzene-1,3-dicarbonitrile Solubility Soluble in DMSO Shipping Conditions Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request category Specialty Chemicals(c26) cas_num 473921-12-9 Basic Info-
Product Name:
3-Cyano-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile
Other Name:Lersivirine(UK 453061);3-Cyano-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]benzonitrile;UK 453061
CAS No.:473921-12-9
Molecular Formula:C17H18N4O2
InChIKeys:MCPUZZJBAHRIPO-UHFFFAOYSA-N
Molecular Weight:310.35
Exact Mass:310.142975
UNII:R3ZGC15A9A
DSSTox ID:DTXSID0057881
NCI Thesaurus Code:C83872
Categories:
Characteristics-
PSA:
94.9
XLogP3:2.1
Density:1.2±0.1 g/cm3
Boiling Point:455.382°C at 760 mmHg
Flash Point:229.2±28.7 °C
Refractive Index:1.595
Hazard IdentificationClassification of the substance or mixture
Reproductive toxicity, Category 2
Specific target organ toxicity â repeated exposure, Category 2
Hazardous to the aquatic environment, long-term (Chronic) - Category Chronic 3
GHS label elements, including precautionary statements
Pictogram(s) 
Signal word Warning
Hazard statement(s) H361 Suspected of damaging fertility or the unborn child
H373 May cause damage to organs through prolonged or repeated exposure
H412 Harmful to aquatic life with long lasting effects
Precautionary statement(s) Prevention P203 Obtain, read and follow all safety instructions before use.
P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...
P260 Do not breathe dust/fume/gas/mist/vapours/spray.
P273 Avoid release to the environment.
Response P318 IF exposed or concerned, get medical advice.
P319 Get medical help if you feel unwell.
Storage P405 Store locked up.
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Coenzymes,Inhibito,Enzymes,Zymogens,Substrates,Native Microorganism Creatine Amidinohydrolase
-
Location:
Shirley, New York 11967, USA
-
Payment Terms:
TT against copy of documents,D/P
-
Average lead Time:
15
-
Total Annual Revenue:
$1 million-$2.5 million
-
Year of Establishment:
2004
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product